$8.3 M

KOOL Mkt cap, 20-Sep-2018

$3.9 M

Cesca Therapeutics Revenue Q2, 2018
Cesca Therapeutics Gross profit (Q2, 2018)715 K
Cesca Therapeutics Gross profit margin (Q2, 2018), %18.5%
Cesca Therapeutics Net income (Q2, 2018)-30.5 M
Cesca Therapeutics EBIT (Q2, 2018)-33.8 M
Cesca Therapeutics Cash, 30-Jun-20183.1 M

Cesca Therapeutics Revenue

Cesca Therapeutics revenue was $11.93 m in FY, 2016 which is a 25.6% year over year decrease from the previous period.

Embed Graph

Cesca Therapeutics Income Statement

Annual

USDFY, 2014FY, 2015FY, 2016

Revenue

16 m16 m11.9 m

Revenue growth, %

0%(26%)

Cost of goods sold

10.1 m11.3 m9.2 m

Gross profit

5.9 m4.7 m2.7 m

Gross profit Margin, %

37%30%23%

Sales and marketing expense

3 m3 m2.1 m

R&D expense

3.5 m5.9 m3.2 m

General and administrative expense

8.5 m10.7 m8.2 m

Operating expense total

14.9 m19.6 m13.6 m

EBIT

(9 m)(14.9 m)(10.9 m)

EBIT margin, %

(57%)(93%)(91%)

Interest expense

1.9 m

Interest income

6 k

Net Income

(8.6 m)(14.9 m)(18.6 m)

Quarterly

USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Revenue

3.7 m4.6 m4 m2.8 m3.3 m2.8 m3.8 m4 m3.3 m3.1 m3.9 m

Cost of goods sold

2.5 m3.1 m2.9 m2.5 m2.3 m2.4 m2.4 m2.5 m1.9 m9.9 m3.2 m

Gross profit

1.2 m1.5 m1.1 m367 k1 m408 k1.4 m1.6 m1.4 m(6.8 m)715 k

Gross profit Margin, %

32%33%28%13%31%14%37%39%42%(221%)18%

Sales and marketing expense

808 k720 k787 k632 k527 k537 k481 k294 k335 k517 k685 k

R&D expense

1.5 m1.5 m1.7 m1.1 m646 k708 k670 k694 k567 k1.1 m1.9 m

General and administrative expense

2.2 m3.6 m3.5 m2.6 m1.8 m1.9 m2.2 m4.1 m2.6 m1.7 m4.6 m

Operating expense total

4.5 m5.9 m6 m4.3 m3 m3.1 m3.3 m5.1 m3.5 m3.3 m34.5 m

Depreciation and amortization

160 k

EBIT

(3.3 m)(4.4 m)(4.8 m)(3.9 m)(2 m)(2.7 m)(1.9 m)(3.6 m)(2.1 m)(2.4 m)(33.8 m)

EBIT margin, %

(90%)(94%)(120%)(139%)(60%)(97%)(52%)(89%)(65%)(77%)(872%)

Interest expense

10.5 m2 k19 k198 k743 k

Interest income

9 k18 k

Income tax expense

3.5 m

Net Income

(3.3 m)(4.4 m)(4.8 m)(3.4 m)(624 k)(10.9 m)(22.4 m)(3.4 m)(2.1 m)(2.6 m)(30.5 m)

Cesca Therapeutics Balance Sheet

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

14.8 m3.4 m5.8 m3.5 m

Accounts Receivable

6.2 k

Inventories

524 m

Current Assets

25.3 m13.3 m12.8 m11.5 m

Goodwill

13.3 m13.2 m13.2 m14 m

Total Assets

62.9 m50.8 m49.9 m51.1 m

Accounts Payable

184.9 k2.6 m2.1 m

Current Liabilities

6.4 m7.9 m5.5 m5.5 m

Total Liabilities

17.6 m17.9 m

Retained Earnings

(122.8 m)(137.7 m)(156.3 m)(187.6 m)

Total Equity

48.7 m34.9 m32.3 m33.2 m

Financial Leverage

1.3 x1.5 x1.5 x1.5 x

Quarterly

USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

10.7 m8.4 m4.8 m6.6 m2.9 m7.2 m5.6 m4.9 m3.8 m2.5 m3.1 m

Accounts Receivable

258 k

Inventories

5.9 m5.2 m5 m4 m4 m3.5 m282 k

Current Assets

21.5 m18.4 m15.7 m14.3 m10.7 m15.1 m12.2 m10.9 m10.6 m10.3 m10.4 m

Goodwill

13.3 m13.2 m13.2 m13.2 m13.2 m13.2 m13.2 m13.2 m13.2 m1.3 m

Total Assets

59.2 m56 m53.4 m51.9 m48.2 m52.4 m49.2 m47.9 m46.8 m48.9 m23.2 m

Accounts Payable

3 m3.2 m4.7 m5.7 m4.4 m3.3 m1.8 m2.1 m1.9 m2 m2 m

Current Liabilities

5.7 m6.6 m8.4 m8.9 m7.4 m5.9 m3.9 m5.4 m4.7 m5 m5.4 m

Total Liabilities

18.1 m14.3 m

Retained Earnings

(126.1 m)(130.5 m)(135.3 m)(141.1 m)(141.7 m)(152.6 m)(178.7 m)(182.1 m)(184.2 m)(187.7 m)(217.3 m)

Total Equity

45.6 m41.6 m37 m32.3 m32.2 m35.8 m36.3 m33.7 m31.8 m30.8 m9 m

Financial Leverage

1.3 x1.3 x1.4 x1.6 x1.5 x1.5 x1.4 x1.4 x1.5 x1.6 x2.6 x

Cesca Therapeutics Cash Flow

Annual

USDFY, 2014FY, 2015FY, 2016

Net Income

(8.6 m)(14.9 m)(18.6 m)

Depreciation and Amortization

993 k1.4 m1.2 m

Accounts Receivable

(2.1 k)(487 )2 m

Inventories

6.4 k42.1 k

Accounts Payable

(2.4 m)

Cash From Operating Activities

(7.8 m)

Cash From Investing Activities

(51 k)(587 k)(710 k)

Cash From Financing Activities

15.8 m(189 k)12.8 m

Free Cash Flow

(8.2 m)

Quarterly

USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q2, 2018

Net Income

(3.3 m)(4.4 m)(4.8 m)(3.4 m)(624 k)(10.9 m)(22.4 m)(3.4 m)(2.1 m)(30.5 m)

Depreciation and Amortization

333 k

Accounts Receivable

869 k

Inventories

5.9 m5.2 m5 m4 m4 m3.5 m(358 k)

Accounts Payable

3 m3.2 m4.7 m5.7 m4.4 m3.3 m1.8 m2.1 m1.9 m(242 k)

Cash From Operating Activities

(6.1 m)

Cash From Investing Activities

(850 k)

Cash From Financing Activities

6.5 m

Interest Paid

657 k

Free Cash Flow

(7 m)

Cesca Therapeutics Ratios

USDY, 2018

Financial Leverage

2.6 x
Report incorrect company information

Cesca Therapeutics Operating Metrics

FY, 2016

Patents Issued

25
Report incorrect company information